Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 1, 2012, Pages 85-91

  Semba, Richard D ^a   Fink, Jeffrey C ^b   Sun, Kai ^a   Cappola, Anne R ^c   Dalal, Mansi ^a   Crasto, Candace ^a   Ferrucci, Luigi ^d   Fried, Linda P ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHATE;

AGED; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; PREVALENCE; RACE; RISK FACTOR; UNITED STATES;

AGED; AGED, 80 AND OVER; CALCITRIOL; CHRONIC DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; RISK;

EID: 84857088991     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08070811     Document Type: Article

References (28)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. Schiffrin EL, Lipman ML, Mann JFE: Chronic kidney disease: Effects on the cardiovascular system. Circulation 116: 85-97, 2007
3. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D: Predictors of new-onset kidney disease in a community-based population. JAMA 291: 844-850, 2004
4. Mei C, Zheng F: Chronic inflammation potentiates kidney aging. Semin Nephrol 29: 555-568, 2009
5. Hori M, Shimizu Y, Fukumoto S: Minireview: Fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152: 4-10, 2011
6. Fukumoto S, Martin TJ: Bone as an endocrine organ. Trends Endocrinol Metab 20: 230-236, 2009
7. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
8. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007
9. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P. MMKD Study Group: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
10. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22: 956-966, 2011
11. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M.Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
12. Wolf M: Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21: 1427-1435, 2010
13. Guralnik JM, Fried LP, Simonsick EM, Kasper D, Lafferty ME: The Women's Health and Aging Study: Health and Social Characteristics of Older Women with Disability, Bethesda, MD, National Institute on Aging, 1995, pp 95-4009
14. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198, 1975
15. US Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services: International Classification of Diseases, 9th Rev., Washington, DC, US Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, 2006
16. Bash LD, Coresh J, Köttgen A, Parekh RS, Fulop T, Wang Y, Astor BC: Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol 170: 414-424, 2009
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
19. Haddad JG, Chyu KJ: Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 33: 992-995, 1971
20. Reinhardt TA, Horst RL, Orf JW, Hollis BW: A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: Application to clinical studies. J Clin Endo-crinol Metab 58: 91-98, 1984
21. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hy-percalcemia. Clin Chem 33: 1364-1367, 1987
22. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF- 23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002
23. O'Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS: Serum phosphate predicts incident chronic kidney disease and end-stage renal disease [published ahead of print February 3, 2011]. Nephrol Dial Transplant doi:10.1093/ndt/gfq808
24. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553-1559, 2011
25. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB: Cir culating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
26. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
27. Anderson J, Glynn LG: Definition of chronic kidney disease and measurement of kidney function in original research papers: A review of the literature [published ahead of print February 9, 2011]. Nephrol Dial Transplant doi:10.1093/ndt/ gfq849
28. Peto R: The horse-racing effect. Lancet 2: 467-468, 1981